A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants
← catalyst calendarSponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 1/2
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
1actual
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Unfavorable benefit-risk assessment
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-17 | actual | When the study began enrolling |
| Primary completion | 2026-07-21 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-21 | actual | The whole study's end, after follow-up |
| First posted | 2025-10-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Active Noninfectious Uveitis Affecting the Posterior Segment
Intervention
- Drug: REGN7041
Primary outcome
what the primary-completion date above is the date OFOccurrence of Treatment-Emergent Adverse Events (TEAEs)
measured Through Week 24
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed